Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

Source · https://www.globenewswire.com/news-release/2026/05/31/3303921/0/en/Johnson-Johnson-s-Phase-3-prostate-cancer-study-shows-ERLEADA-apalutamide-before-and-after-surgery-significantly-reduces-risk-of-metastasis-or-death-versus-hormone-therapy-alone-po.html

Read source

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

Story key points

0 claims · impact-rated

What matters in this story

No key-points head found for this article.

Ticker attribution

Model heads

Sentiment in this article

No ticker sentiment head found.

Relationships in this article

No ticker relationship head found.

Impact vectors

0 dimensions · 9 clusters

Analytical profile by cluster

Macro Sensitivity+0.000
Sector Rotation+0.000

News Impact Screener — Catch market-moving news before the crowd

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted